A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses

PHASE4CompletedINTERVENTIONAL
Enrollment

334

Participants

Timeline

Start Date

January 20, 2023

Primary Completion Date

January 19, 2024

Study Completion Date

January 19, 2024

Conditions
Actinic Keratosis
Interventions
DRUG

Tirbanibulin 2.5 mg ointment

Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm\^2) of the face or scalp.

Trial Locations (37)

Unknown

Almirall Investigational Site 1, Cagliari

Almirall Investigational Site 2, Catania

Almirall Investigational Site 3, Napoli

Almirall Investigational Site 4, Pisa

Almirall Investigational Site 5, Rimini

Almirall Investigational Site 6, Torino

Almirall Investigational Site 7, Trieste

Almirall Investigational Site 1, Alcorcón

Almirall Investigational Site 2, Alicante

Almirall Investigational Site 3, Badalona

Almirall Investigational Site 4, Barcelona

Almirall Investigational Site 5, Barcelona

Almirall Investigational Site 6, Barcelona

Almirall Investigational Site 7, Barcelona

Almirall Investigational Site 8, Bilbao

Almirall Investigational Site 9, Córdoba

Almirall Investigational Site 10, Fuenlabrada

Almirall Investigational Site 11, Granada

Almirall Investigational Site 12, Madrid

Almirall Investigational Site 13, Madrid

Almirall Investigational Site 14, Madrid

Almirall Investigational Site 15, Madrid

Almirall Investigational Site 16, Majadahonda

Almirall Investigational Site 17, Málaga

Almirall Investigational Site 18, Palma

Almirall Investigational Site 19, Pontevedra

Almirall Investigational Site 20, Sabadell

Almirall Investigational Site 21, Salamanca

Almirall Investigational Site 22, Santa Cruz de Tenerife

Almirall Investigational Site 23, Seville

Almirall Investigational Site 24, Seville

Almirall Investigational Site 25, Valencia

Almirall Investigational Site 26, Valencia

Almirall Investigational Site 27, Valencia

Almirall Investigational Site 28, Vigo

Almirall Investigational Site 29, Zaragoza

Almirall Investigational Site 30, Zaragoza

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY

NCT05741294 - A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses | Biotech Hunter | Biotech Hunter